Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next Year

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next Year
SAREPTA THERAP (NASDAQ: SRPT) Delayed: 20.11 -0.56 (2.71%)
Previous Close $20.67    52 Week High $63.73 
Open $20.63    52 Week Low $8.00 
Day High $20.74    P/E N/A 
Day Low $19.62    EPS $-5.69 
Volume 6,292,416